GlassScriptPhysician profile
Alex J Blanco
NPI 1962573055
$3,553.93
in general payments reported to CMS, 2019-2025
28 companies · $172 in 2025
The $172 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $951 · 2020: $460 · 2021: $555 · 2022: $441 · 2023: $657 · 2024: $318 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,146.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $716.67 | 2019-2023 | Farxiga |
| Novo Nordisk INC | $386.46 | 2019-2024 | Wegovy, Saxenda |
| Lilly USA, LLC | $297.33 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $285.97 | 2022-2024 | Vraylar, Qulipta, Ubrelvy |
| Amgen INC. | $265.29 | 2020-2025 | Otezla, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $259.68 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $231.64 | 2019-2024 | Xifaxan |
| Eisai INC. | $160.71 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.62 | 2019-2023 | Jardiance |
| Daiichi Sankyo INC. | $103.63 | 2019-2022 | |
| Amarin Pharma, INC. | $83.05 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $81.60 | 2023 | |
| Pfizer INC. | $57.99 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $56.77 | 2023-2024 | Rexulti |
| Glaxosmithkline, LLC. | $54.88 | 2021-2023 | Arexvy, Shingrix |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $52.47 | 2021 | |
| Sanofi-Aventis U.S. LLC | $44.37 | 2019-2023 | |
| Vanda Pharmaceuticals INC. | $38.30 | 2020 | |
| Radius Health, INC. | $36.12 | 2023-2025 | Tymlos |
| Novartis Pharmaceuticals Corporation | $31.54 | 2021-2023 | |
| Nestle Healthcare Nutrition INC. | $30.89 | 2021 | |
| Melinta Therapeutics, LLC | $30.24 | 2020 | |
| Esperion Therapeutics, INC. | $26.59 | 2021 | |
| Lundbeck LLC | $22.84 | 2025 | Rexulti |
| Ani Pharmaceuticals, INC. | $19.81 | 2025 | Purified Cortrophin Gel |
| Janssen Pharmaceuticals, INC | $18.35 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $17.56 | 2024 | Austedo Xr |
| Phadia US INC. | $17.56 | 2024 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Blanco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.